142 related articles for article (PubMed ID: 18559974)
21. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity.
Zhao L; Buckman B; Seto M; Morser J; Nagashima M
J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375
[TBL] [Abstract][Full Text] [Related]
23. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
24. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
25. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor.
Marx PF; Bouma BN; Meijers JC
Biochemistry; 2002 Jan; 41(4):1211-6. PubMed ID: 11802720
[TBL] [Abstract][Full Text] [Related]
26. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI.
Hillmayer K; Macovei A; Pauwels D; Compernolle G; Declerck PJ; Gils A
J Thromb Haemost; 2006 Nov; 4(11):2470-7. PubMed ID: 17002650
[TBL] [Abstract][Full Text] [Related]
27. Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.
Valnickova Z; Sanglas L; Arolas JL; Petersen SV; Schar C; Otzen D; Aviles FX; Gomis-Rüth FX; Enghild JJ
J Biol Chem; 2010 Dec; 285(49):38243-50. PubMed ID: 20880845
[TBL] [Abstract][Full Text] [Related]
28. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
Plug T; Meijers JC
J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
[TBL] [Abstract][Full Text] [Related]
29. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).
Valnickova Z; Thaysen-Andersen M; Højrup P; Christensen T; Sanggaard KW; Kristensen T; Enghild JJ
BMC Biochem; 2009 May; 10():13. PubMed ID: 19416536
[TBL] [Abstract][Full Text] [Related]
30. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
Bazzi ZA; Balun J; Cavallo-Medved D; Porter LA; Boffa MB
Clin Exp Metastasis; 2017 Feb; 34(2):155-169. PubMed ID: 28124276
[TBL] [Abstract][Full Text] [Related]
31. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?
Marx PF; Plug T; Havik SR; Mörgelin M; Meijers JC
J Thromb Haemost; 2009 Mar; 7(3):445-52. PubMed ID: 19054324
[TBL] [Abstract][Full Text] [Related]
32. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
[TBL] [Abstract][Full Text] [Related]
33. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor.
Marx PF; Dawson PE; Bouma BN; Meijers JC
Biochemistry; 2002 May; 41(21):6688-96. PubMed ID: 12022872
[TBL] [Abstract][Full Text] [Related]
34. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
[TBL] [Abstract][Full Text] [Related]
35. Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
Semeraro F; Mancuso ME; Ammollo CT; Dirienzo L; Vitulli A; Santagostino E; Tripodi A; Colucci M
J Thromb Haemost; 2020 Feb; 18(2):381-389. PubMed ID: 31571361
[TBL] [Abstract][Full Text] [Related]
36. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.
Bouma BN; Mosnier LO; Meijers JC; Griffin JH
Thromb Haemost; 1999 Dec; 82(6):1703-8. PubMed ID: 10613658
[TBL] [Abstract][Full Text] [Related]
37. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB
BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823
[TBL] [Abstract][Full Text] [Related]
38. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor.
Buelens K; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
J Thromb Haemost; 2010 Jun; 8(6):1302-12. PubMed ID: 20180900
[TBL] [Abstract][Full Text] [Related]
39. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
40. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
Bajzar L; Jain N; Wang P; Walker JB
Crit Care Med; 2004 May; 32(5 Suppl):S320-4. PubMed ID: 15118538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
